VITALGEN
Vitalgen is a biopharmaceutical company that focuses on the research and development of gene therapeutics. The company is committed to transforming cutting-edge gene and cell therapy technologies into clinically accessible treatments, with the hope of benefiting more many patients. It utilizes CRISPR gene-editing technology to research and develop revolutionary gene therapy to significantly improve the quality of life of patients. Vitalgen was founded in 2020 and is headquartered in Shanghai, China.
VITALGEN
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical Therapeutics
Founded:
2019-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.vitalgen-biomed.com
Total Employee:
1+
Status:
Active
Contact:
021-50309339
Email Addresses:
[email protected]
Technology used in webpage:
Euro Pound Sterling Japanese Yen Chinese Server Location
Similar Organizations
Adgero Biopharmaceuticals
Adgero Biopharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on building a robust pipeline
Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics.
Anthos Therapeutics
Anthos Therapeutics is a biopharmaceutical company that specializes in the treatment of cardiovascular and metabolic diseases.
Heyuan Biotechnology
A leading high-tech enterprise of biomedical basic research, gene therapy drug incubation, and clinical-level gene therapy
Marinomed
Marinomed is a biopharmaceutical company that develops innovative anti-viral and immunological treatments.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Silenseed
Silenseed is a biopharmaceutical company that focuses on the development of cancer therapies.
VelaVigo
VelaVigo is a start-up company engaged in macromolecular biopharmaceutical.
Current Employees Featured
Founder
Official Site Inspections
http://www.vitalgen-biomed.com
- Host name: 218.5.76.48
- IP address: 218.5.76.48
- Location: China
- Latitude: 24.4798
- Longitude: 118.0819
- Timezone: Asia/Shanghai
More informations about "Vitalgen"
Shanghai Vitalgen BioPharma Co., Ltd
Since founded in March 2020, Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen) has committed to translating cutting edge discoveries and technologies in cell and gene therapy into clinically …See details»
上海天泽云泰生物医药有限公司
公司拥有一支由业内顶尖的学术专家和经验丰富的研发人员组成的团队，覆盖了药物开发从概念到上市的每一环节；拥有具有自主知识产权的一系列核心技术平台，包括ViVec AAV载体筛选平 …See details»
关于Vitalgen | Shanghai Vitalgen BioPharma Co., Ltd
We are committed to connecting cutting edge technologies to improve quality of life in patients, through tireless hard work to translate gene delivery and gene editing technologies into …See details»
Vitalgen - Crunchbase Company Profile & Funding
Vitalgen is a biopharmaceutical company that focuses on the research and development of gene therapeutics. The company is committed to transforming cutting-edge gene and cell therapy …See details»
Vitalgen BioPharma Co., Ltd. | BIO-Europe Spring
Vitalgen was founded in March 2020 and focused on the delivery of innovative therapeutics to patients to fulfill unmet medical needs. We have in-house developed virus and non-virus drug …See details»
Vitalgen Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Vitalgen. Use the PitchBook Platform to explore the full profile.See details»
上海天泽云泰生物医药有限公司 | LinkedIn
让所有疾病都有治愈的机会 | 天泽云泰（Vitalgen）致力于将前沿的基因递送和基因编辑技术，转化为治疗遗传性及退行性疾病的创新疗法。 通过应用具有自主知识产权的AAV衣壳和全新 …See details»
Shanghai Vitalgen Biopharma Co., Ltd. - synapse.zhihuiya.com
恒瑞医药子公司上海瑞宏迪医药的RGL-193，是一款AAV双基因药物，靶基因尚不明，根据公司公告RGL-193可以提高左旋多巴的转化效率，同时还起到保护和修复受损多巴胺能神经元的作 …See details»
Vitalgen - Products, Competitors, Financials, Employees, …
Vitalgen is committed to transforming cutting-edge gene delivery and gene editing technologies into innovative therapies for the treatment of genetic diseases, benefiting more patients with …See details»
News | Milestone of BCD gene therapy: Vitalgen VGR-R01 IND …
VGR-R01 is a gene therapy product independently developed by Vitalgen for patients with Bietti crystalline dystrophy (BCD) caused by CYP4V2 gene mutation. It is also the first therapeutic …See details»
News | Vitalgen completed the enrollment in the Phase …
On September 21, 2023, the surgical administration of all subjects was successfully completed in the Phase I/II clinical trial of VGR-R01, marking another critical step toward the marketing of this world-first therapeutic product.See details»
News | - Shanghai Vitalgen BioPharma Co., Ltd
Prev: Recent Progresses in Gene Therapy Presented by Vitalgen BioPharma at the ASGCT Annual Meeting. Next: The first in vivo gene therapy product developed in China for …See details»
Shanghai Vitalgen BioPharma | VentureRadar
Since founded in March 2020, Shanghai Vitalgen BioPharma Co., Ltd. (Vitalgen) has committed to translatinge cutting edge discoveries and technologies in cell and gene therapy into clinically …See details»
新闻资讯 | -上海天泽云泰生物医药有限公司 - vitalgen.com
VGN-R08b是天泽云泰自主开发的基因治疗产品，是一种针对II型戈谢氏病（GD）的单剂量、基于腺相关病毒（AAV）的基因替代疗法。 当通过侧脑室注射（Intracerebroventricular，ICV）注 …See details»
Science | Shanghai Vitalgen BioPharma Co., Ltd
LNP-based delivery system has the potential to provide hit-and-run gene editing to selectively knock out disease-causing genes, introduce safe-harbor targeted insertion of a functional gene …See details»
Shanghai Vitalgen BioPharma Co., Ltd. - discovery.patsnap.com
Nov 30, 2022 · Shanghai Vitalgen BioPharma Co., Ltd. is located in Asia, China. Free Competitive Analysis! Sign up to get free competitive intelligence for millions of companies!See details»
News | - Shanghai Vitalgen BioPharma Co., Ltd
（Shanghai, China, October 16, 2021），Shanghai Vitalgen BioPharma Co., Ltd. has raised 200 million RMB Series A+ funding round. The financing is led by Hillhouse. Other new and …See details»
Vitalgen Stock Price, Funding, Valuation, Revenue & Financial …
See Vitalgen funding rounds, investors, investments, exits and more. Evaluate their financials based on Vitalgen's post-money valuation and revenue.See details»
News | Shanghai Vitalgen BioPharma Co., Ltd
On July 5, 2024, the Phase 1/2 clinical study of the gene therapy drug VGN-R09b Injection for treatment of primary Parkinson's disease self-developed by Shanghai Vitalgen BioPharma …See details»
Shanghai Vitalgen BioPharma - VentureRadar
Website: http://www.vitalgen-biomed.com/ Develops innovative cell and gene therapies for hereditary diseases, neurodegenerative diseases, and cancers using proprietary technologies …See details»